S-1

Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: Phase 3 Trial

A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.